Remarkably, the gene signature derived from the Vδ2− subset correlated with improved survival in kidney cancer patient data from the TCGA database, as well as with improved clinical response in patients with RCC and urothelial cancer treated with PD-1 blockade. This evidence concerns the gene PDCD1 and kidney cancer.